Preliminary feasibility study on differential diagnosis between radiation-induced cerebral necrosis and recurrent brain tumor by means of [18F]fluoro-borono-phenylalanine PET/CT

Rouaa Beshr,Kayako Isohashi,Tadashi Watabe,Sadahiro Naka,Genki Horitsugi,Victor Romanov,Hiroki Kato,Shin-Ichi Miyatake,Eku Shimosegawa,Jun Hatazawa
DOI: https://doi.org/10.1007/s12149-018-1296-2
2018-09-07
Annals of Nuclear Medicine
Abstract:<h3 class="a-plus-plus">Abstract</h3> <span class="a-plus-plus abstract-section id-a-sec1"> <h3 class="a-plus-plus">Objectives</h3> <p class="a-plus-plus">A previous study reported that a differential diagnosis between glioblastoma progression and radiation necrosis by 4-borono-2-[<sup class="a-plus-plus">18</sup>F]-fluoro-phenylalanine ([<sup class="a-plus-plus">18</sup>F]FBPA) PET can be made based on lesion-to-normal ratio of [<sup class="a-plus-plus">18</sup>F]FBPA accumulation. Two-dimensional data acquisition mode PET alone system, with in-plane resolution of 7.9 mm and axial resolution of 13.9 mm, was used. In the current study, we aimed to confirm the differential diagnostic capability of [<sup class="a-plus-plus">18</sup>F]FBPA PET/CT with higher PET spatial resolution by three-dimensional visual inspection and by measuring mean standardized uptake value (SUVmean), maximum SUV (SUVmax), metabolic tumor volume (MTV), and total lesion (TL) [<sup class="a-plus-plus">18</sup>F]FBPA uptake.</p> </span> <span class="a-plus-plus abstract-section id-a-sec2"> <h3 class="a-plus-plus">Methods</h3> <p class="a-plus-plus">Twelve patients of glioma (9), malignant meningioma (1), hemangiopericytoma (1), and metastatic brain tumor (1) were enrolled. All had preceding radiotherapy. High-resolution three-dimensional data acquisition mode PET/CT with in-plane resolution of 4.07 mm and axial resolution of 5.41 mm was employed for imaging. Images were three-dimensionally analyzed using the PMOD software. SUVmean and SUVmax of lesion and normal brain were measured. Lesion MTV and TL FBPA uptake were calculated. The diagnostic accuracy of [<sup class="a-plus-plus">18</sup>F]FBPA PET/CT in detecting recurrence (<em class="a-plus-plus">n</em> = 6) or necrosis (<em class="a-plus-plus">n</em> = 6) was verified by clinical follow-up.</p> </span> <span class="a-plus-plus abstract-section id-a-sec3"> <h3 class="a-plus-plus">Results</h3> <p class="a-plus-plus">All parameters showed significantly higher values for tumor recurrence than for necrosis. SUVmean in recurrence was 2.95 ± 0.84 vs 1.18 ± 0.24 in necrosis (<em class="a-plus-plus">P</em> = 0.014); SUVmax in recurrence was 4.63 ± 1.23 vs 1.93 ± 0.44 in necrosis (<em class="a-plus-plus">P</em> = 0.014); MTV in recurrence was 44.92 ± 28.93 mL vs 10.66 ± 8.46 mL in necrosis (<em class="a-plus-plus">P</em> = 0.032); and mean TL FBPA uptake in recurrence was 121.01 ± 50.48 g vs 12.36 ± 9.70 g in necrosis (<em class="a-plus-plus">P</em> = 0.0029).</p> </span> <span class="a-plus-plus abstract-section id-a-sec4"> <h3 class="a-plus-plus">Conclusion</h3> <p class="a-plus-plus">In this preliminary feasibility study, we confirmed the possibility of differentiating tumor recurrence from radiation necrosis in patients with irradiated brain tumors by [<sup class="a-plus-plus">18</sup>F]FBPA PET/CT using indices of SUVmean, SUVmax, MTV, and TL <sup class="a-plus-plus">18</sup>FBPA uptake.</p> </span>
radiology, nuclear medicine & medical imaging
What problem does this paper attempt to address?